Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.50 |
| ▸ | MB | P02144 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydantoin SCHEMBL10578141 | 1.00 | — | — | |
| Hydantoin SCHEMBL7285865 | 0.97 | — | — | |
| Hydantoin SCHEMBL27690 | 0.97 | — | — | |
| Hydantoin SCHEMBL27705088 | 0.97 | CRBN (0.52) | CRBNMBALDH1A1CYP1A2HPGD | |
| Hydantoin SCHEMBL10770473 | 0.94 | — | — | |
| Hydantoin SCHEMBL1786052 | 0.94 | — | — | |
| Hydantoin SCHEMBL3479397 | 0.94 | — | — | |
| Hydantoin SCHEMBL3246334 | 0.94 | — | — | |
| Hydantoin SCHEMBL8639680 | 0.94 | — | — | |
| Hydantoin SCHEMBL22371823 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0112620-B1 | 5-(SUBSTITUTED PHENYL) HYDANTOINS | PFIZER INC. (US) | 1986-12-30 | — | — | EP | claimed |
| EP-0112620-A1 | 5-(Substituted phenyl) hydantoins | PFIZER INC. (US) | 1984-07-04 | — | — | EP | claimed |
| US-7041693-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1546109-A4 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME (TACE) | BRISTOL MYERS SQUIBB CO (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1546109-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME (TACE) | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004033632-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040067996-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-08 | — | — | US | disclosed |
| EP-0112620-B1 | 5-(SUBSTITUTED PHENYL) HYDANTOINS | PFIZER INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| EP-0112620-A1 | 5-(Substituted phenyl) hydantoins | PFIZER INC. (US) | 1984-07-04 | — | — | EP | disclosed |
| US-4452806-A | Treating diabetic complications with 5-(substituted phenyl)hydantoins | PFIZER INC. (US) | 1984-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067996-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, ADAMTS1 | CRBN 4765/4885MB 2340/4885ALDH1A1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.